Amgen Launches Two Phase 3 Trials for Obesity Drug MariTide
Amgen has launched two phase 3 trials for its obesity drug MariTide, as announced by Jay Bradner, Head of Research and Development. One trial targets individuals with obesity or overweight without type 2 diabetes, aiming to enroll 3,500 participants. The second trial focuses on those with obesity or overweight and type 2 diabetes, with a target enrollment of 999 patients. The studies will evaluate various dose levels, with the primary endpoint being the change in baseline body weight at 72 weeks.
Amgen has initiated two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference.
One of the trials is in people with obesity or overweight without type 2 diabetes, and is expected to enroll 3,500 people, Bradner said. The second trial is in people with obesity or overweight who have type 2 diabetes, with Amgen intending to enroll 999 patients, he added.
The studies will test different dose levels, starting at a lower dose. Bradner said the primary endpoint is the change in baseline body weight at 72 weeks.